Bringing COVID-19 vaccines to the public

Once a vaccine to prevent COVID-19 is approved, there will be logistics to consider. For example, who will receive the vaccine first, and how can the supply chain safely deliver the vaccine to 330 million Americans and potentially more than 7 billion people worldwide? In addition, multiple vaccines may be brought to market within weeks to months of each other, confusing consumers.

On the Mayo Clinic Q&A podcast, Dr. Gregory Poland, an infectious diseases expert and head of Mayo Clinic's Vaccine Research Group, explains the challenges of rolling out a COVID-19 vaccine.

To practice safe social distancing during the COVID-19 pandemic, this interview was conducted using video conferencing. The sound and video quality are representative of the technology used.

Connect with others talking about the pandemic and supporting one another in the COVID-19 support group.

Dr. Poland has served as a consultant for Merck & Co. Inc., Medicago Inc., GlaxoSmithKline plc, Sanofi Pasteur, Emergent BioSolutions Inc., Dynavax Technologies Corp., Genentech Inc., Eli Lilly and Co., Kentucky BioProcessing Inc. and Genevant Sciences Corp., and Janssen Pharmaceuticals Inc. He is a paid scientific adviser for Johnson & Johnson. Honoraria: Elsevier.